RBC Lowers Price Target on Edgewise Therapeutics to $52 From $56, Keeps Outperform, Speculative Risk

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

RBC Lowers Price Target on Edgewise Therapeutics to $52 From $56, Keeps Outperform, Speculative Risk

, MT Newswires - 6:43 AM ET 4/3/2025 default

06:43 AM EDT, 04/03/2025 (MT Newswires) -- Edgewise Therapeutics ( EWTX ) has an average rating of buy and mean price target of $42.78, according to analysts polled by FactSet.

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.